Author

D C Talbot

Observed names: D Talbot, D. C. Talbot, D. Talbot, D.C Talbot, D.C. TALBOT, D.C. Talbot, DENIS C. TALBOT, David Talbot, Talbot, D.C

Observed institutions: Cliniques Universitaires Saint-Luc, Royal Marsden NHS Foundation Trust, Beatson West of Scotland Cancer Centre, Glasgow Royal Infirmary, Churchill Hospital, Cancer Research UK, Hammersmith Hospital, The Netherlands Cancer Institute, University of Oxford, Royal Marsden Hospital, The Christie Hospital, King's College Hospital, Imperial College London, Newcastle University

OpenAlex ID: A5110067223

Prognostic Value of Angiogenesis in Operable Non-small Cell Lung Cancer

1996 · ALEXANDRA GIATROMANOLAKI, MICHAEL KOUKOURAKIS, et al. · The Journal of Pathology · 169

Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions.

1999 · V M Macaulay, K J O'Byrne, et al. · PubMed · 161

Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.

2001 · N C Levitt, F A Eskens, et al. · PubMed · 134

Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer.

1991 · D C Talbot, I E Smith, et al. · Journal of Clinical Oncology · 61

Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results.

1996 · W P Steward, D J Dunlop, et al. · PubMed · 58

Chemotherapy should not be withheld from patients with an indwelling pleural catheter for malignant pleural effusion

2010 · A. Morel, E. Mishra, et al. · Thorax · 55

PDF

The development of a structured rating schedule (the BAS) to assess skills in breaking bad news

1999 · S J Miller, T Hope, et al. · British Journal of Cancer · 47

PDF

The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study

2007 · W.P. Steward, M. Middleton, et al. · Annals of Oncology · 46

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours

2011 · L Medley, A N Morel, et al. · British Journal of Cancer · 35

PDF

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer

2011 · O A Khan, A D Blann, et al. · British Journal of Cancer · 34

PDF

Use of Positron Emission Tomography in Pharmacokinetic Studies to Investigate Therapeutic Advantage in a Phase I Study of 120-Hour Intravenous Infusion XR5000

2003 · D.J. Propper, J. de Bono, et al. · Journal of Clinical Oncology · 33

Some Observations on the Reversibility of Methotrexate Toxicity in Normal Proliferating Tissues2

1977 · J. A. Straw, D. C. Talbot, et al. · JNCI Journal of the National Cancer Institute · 28

Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer

2003 · J.P Braybrooke, M Ranson, et al. · Lung Cancer · 23

Phase I study of seliciclib (CYC202 or R-roscovitine) in combination with gemcitabine (gem)/cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC)

2005 · W. S. Siegel-Lakhai, D. O. Rodenstein, et al. · Journal of Clinical Oncology · 22

Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine

2000 · D J Propper, J P Braybrooke, et al. · British Journal of Cancer · 19

PDF

Signet-ring cell lymphoma of bone marrow.

1994 · D C Talbot, J H Davies, et al. · Journal of Clinical Pathology · 15

PDF

Inefficacy of calcipotriol In skin metastases from breast cancer

1993 · M.E.R. O'Brien, D. Talbot, et al. · The Lancet · 13

Chylous ascites in Kaposi's sarcoma: a case report

1992 · K.M. FIFE, D.C. TALBOT, et al. · British Journal of Dermatology · 13

A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract

1997 · J.P. Braybrooke, K.J. O’Byrne, et al. · Annals of Oncology · 8

PDF

Pharmacodynamic (PD) evaluation of LY2181308 in patients with metastatic malignancies

2009 · D. C. Talbot, J. Davies, et al. · Journal of Clinical Oncology · 7

Dose intensification of carboplatin and etoposide as first-line combination chemotherapy in small cell lung cancer

1995 · P.A. Ellis, D.C. Talbot, et al. · European Journal of Cancer · 6

Teicoplanin compared to flucloxacillin for antibiotic treatment of neutropenic patients

1990 · Carole L. Smith, S. Milliken, et al. · British Journal of Haematology · 6

Safety and efficacy of DHA-paclitaxel (TXP) in non-small cell lung cancer (NSCLC)

2004 · L. Schacter, D. Talbot, et al. · Journal of Clinical Oncology · 5

New perspectives in lung cancer.5. New drugs in lung cancer.

1992 · D C Talbot, I E Smith · Thorax · 5

PDF

A Randomized Double-Blind Placebo Controlled Trial of Medroxyprogesterone Acetate (Mpa) in Cancer Cachexia

1988 · D C Talbot, M L Slevin, et al. · British Journal of Cancer · 5

Works count: 47

Citation count: 1,020

H-index: 15

I10-index: 18